BR112016018581A2 - Processo para a fabricação de derivados de sulfamida pirimidina - Google Patents

Processo para a fabricação de derivados de sulfamida pirimidina

Info

Publication number
BR112016018581A2
BR112016018581A2 BR112016018581A BR112016018581A BR112016018581A2 BR 112016018581 A2 BR112016018581 A2 BR 112016018581A2 BR 112016018581 A BR112016018581 A BR 112016018581A BR 112016018581 A BR112016018581 A BR 112016018581A BR 112016018581 A2 BR112016018581 A2 BR 112016018581A2
Authority
BR
Brazil
Prior art keywords
sulfamide
manufacturing
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
BR112016018581A
Other languages
English (en)
Other versions
BR112016018581B1 (pt
BR112016018581A8 (pt
Inventor
Schindelholz Ivan
Funel Jacques-Alexis
Abele Stefan
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016018581(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to BR122017005939-4A priority Critical patent/BR122017005939B1/pt
Publication of BR112016018581A2 publication Critical patent/BR112016018581A2/pt
Publication of BR112016018581A8 publication Critical patent/BR112016018581A8/pt
Publication of BR112016018581B1 publication Critical patent/BR112016018581B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
BR112016018581-1A 2014-02-14 2015-02-13 Processo para a fabricação de derivados de sulfamida pirimidina BR112016018581B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122017005939-4A BR122017005939B1 (pt) 2014-02-14 2015-02-13 Processo para a fabricação de derivados de sulfamida pirimidina

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14155137.4 2014-02-14
EP14155137.4A EP2907811A1 (en) 2014-02-14 2014-02-14 Process for manufacturing pyrimidine sulfamide derivatives
PCT/EP2015/053047 WO2015121397A1 (en) 2014-02-14 2015-02-13 Process for manufacturing pyrimidine sulfamide derivatives

Publications (3)

Publication Number Publication Date
BR112016018581A2 true BR112016018581A2 (pt) 2017-08-08
BR112016018581A8 BR112016018581A8 (pt) 2021-06-22
BR112016018581B1 BR112016018581B1 (pt) 2022-11-16

Family

ID=50073084

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122017005939-4A BR122017005939B1 (pt) 2014-02-14 2015-02-13 Processo para a fabricação de derivados de sulfamida pirimidina
BR112016018581-1A BR112016018581B1 (pt) 2014-02-14 2015-02-13 Processo para a fabricação de derivados de sulfamida pirimidina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122017005939-4A BR122017005939B1 (pt) 2014-02-14 2015-02-13 Processo para a fabricação de derivados de sulfamida pirimidina

Country Status (28)

Country Link
US (1) US9938244B2 (pt)
EP (3) EP2907811A1 (pt)
JP (2) JP6431922B2 (pt)
KR (2) KR102261695B1 (pt)
CN (2) CN107162988B (pt)
AR (2) AR099434A1 (pt)
AU (2) AU2015217000B2 (pt)
BR (2) BR122017005939B1 (pt)
CA (1) CA2937277C (pt)
CL (2) CL2016002008A1 (pt)
CY (1) CY1123319T1 (pt)
DK (1) DK3105220T3 (pt)
EA (2) EA032460B1 (pt)
ES (2) ES2906458T3 (pt)
HK (1) HK1243405A1 (pt)
HR (1) HRP20201450T1 (pt)
HU (1) HUE050974T2 (pt)
IL (1) IL251126A0 (pt)
LT (1) LT3105220T (pt)
MX (1) MX368014B (pt)
NZ (1) NZ724273A (pt)
PL (1) PL3105220T3 (pt)
PT (1) PT3105220T (pt)
SA (1) SA516371640B1 (pt)
SG (2) SG11201606667VA (pt)
SI (1) SI3105220T1 (pt)
TW (2) TWI666203B (pt)
WO (1) WO2015121397A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095727A1 (es) 2013-03-27 2015-11-04 Actelion Pharmaceuticals Ltd Preparación de intermediarios de pirimidina
EP2907811A1 (en) * 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
CN105461639B (zh) * 2015-12-10 2018-03-09 合肥久诺医药科技有限公司 一种高纯度马西替坦的精制方法
CN105461638A (zh) * 2015-12-10 2016-04-06 合肥久诺医药科技有限公司 一种马西替坦晶型及其制备方法
CN110325186A (zh) * 2017-02-27 2019-10-11 爱杜西亚药品有限公司 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与活性成分的组合
CN109232546B (zh) * 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
EP4056182A1 (en) * 2019-11-07 2022-09-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of aprocitentan, preparation method therefor and use thereof
EP4153574A1 (en) * 2020-05-21 2023-03-29 Teva Pharmaceuticals International GmbH Solid state forms of aprocitentan and process for preparation thereof
WO2023111797A1 (en) * 2021-12-17 2023-06-22 Janssen Biotech, Inc. Pyrimidine sulfamide derivatives and process for manufacturing them
WO2023227721A1 (en) 2022-05-25 2023-11-30 Idorsia Pharmaceuticals Ltd Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3921918A1 (de) * 1989-07-04 1991-01-17 Hoechst Ag Verfahren zur herstellung von 2,4,6-trifluor-1,3,5-triazin
EP1345920B1 (en) 2000-12-18 2006-04-12 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
TR200103716A2 (tr) * 2001-12-25 2003-07-21 Ba�Lama Al� Zenginleştirilmiş dizel yakıt kompozisyonu
DE60224223T2 (de) * 2002-01-02 2008-12-04 Actelion Pharmaceuticals Ltd. Neue alkylsulfonamide als endothelinantagonisten
MX2010001837A (es) * 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
ES2435804T3 (es) 2009-02-13 2013-12-23 Bayer Intellectual Property Gmbh Pirimidinas condensadas como inhibidores de Akt
US20110082151A1 (en) * 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
KR101471047B1 (ko) * 2012-11-21 2014-12-08 주식회사 메디켐코리아 고순도 보센탄의 개선된 제조방법
CN103012279B (zh) * 2012-11-27 2015-01-28 浙江工业大学 一种4,5,6-三氟嘧啶化合物的制备方法
AR095727A1 (es) 2013-03-27 2015-11-04 Actelion Pharmaceuticals Ltd Preparación de intermediarios de pirimidina
CN103724281A (zh) * 2013-12-03 2014-04-16 镇江圣安医药有限公司 N-[5-(4-溴苯基)-6-[2-[(5-溴-2-嘧啶基)氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用
EP2907811A1 (en) * 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives

Also Published As

Publication number Publication date
CY1123319T1 (el) 2021-12-31
HUE050974T2 (hu) 2021-01-28
EA032933B1 (ru) 2019-08-30
SI3105220T1 (sl) 2020-10-30
TWI666203B (zh) 2019-07-21
JP2017505801A (ja) 2017-02-23
SG10201701994RA (en) 2017-05-30
HK1243405A1 (zh) 2018-07-13
CA2937277C (en) 2021-07-06
CL2017000505A1 (es) 2017-11-24
JP2017125055A (ja) 2017-07-20
JP6431922B2 (ja) 2018-11-28
MX2016010486A (es) 2016-10-31
MX368014B (es) 2019-09-13
BR122017005939B1 (pt) 2022-12-20
SA516371640B1 (ar) 2019-09-08
CN105992762B (zh) 2019-04-16
AU2015217000A1 (en) 2016-09-29
EP3214082B1 (en) 2021-11-10
CN107162988A (zh) 2017-09-15
KR102261695B1 (ko) 2021-06-07
HRP20201450T1 (hr) 2020-12-25
ES2906458T3 (es) 2022-04-18
BR112016018581B1 (pt) 2022-11-16
TWI663155B (zh) 2019-06-21
NZ724273A (en) 2020-06-26
AU2017202446B2 (en) 2019-03-28
LT3105220T (lt) 2020-10-12
EP3105220A1 (en) 2016-12-21
TW201730157A (zh) 2017-09-01
EA201790343A1 (ru) 2017-06-30
AU2017202446A1 (en) 2017-05-04
KR102406358B1 (ko) 2022-06-07
CN105992762A (zh) 2016-10-05
DK3105220T3 (da) 2020-09-07
CA2937277A1 (en) 2015-08-20
CN107162988B (zh) 2020-08-21
AR099434A1 (es) 2016-07-20
PT3105220T (pt) 2020-09-23
US9938244B2 (en) 2018-04-10
EP3214082A1 (en) 2017-09-06
BR122017005939A2 (pt) 2019-09-10
KR20160122213A (ko) 2016-10-21
PL3105220T3 (pl) 2020-12-28
NZ729685A (en) 2020-11-27
SG11201606667VA (en) 2016-09-29
CL2016002008A1 (es) 2017-02-03
WO2015121397A1 (en) 2015-08-20
AR107801A2 (es) 2018-06-06
ES2819504T3 (es) 2021-04-16
TW201613877A (en) 2016-04-16
EA032460B1 (ru) 2019-05-31
EA201691618A1 (ru) 2017-01-30
BR112016018581A8 (pt) 2021-06-22
JP6421209B2 (ja) 2018-11-07
EP3105220B1 (en) 2020-07-01
EP2907811A1 (en) 2015-08-19
US20160368882A1 (en) 2016-12-22
AU2015217000B2 (en) 2019-02-14
IL251126A0 (en) 2017-04-30
KR20170029656A (ko) 2017-03-15

Similar Documents

Publication Publication Date Title
BR112016018581A2 (pt) Processo para a fabricação de derivados de sulfamida pirimidina
BR112016013492A2 (pt) processo para a preparação de ácidos alcanossulfônicos.
ES2864754T8 (es) Método de producción de metionina
DK3341479T3 (da) LNA-G-Proces
DK3132111T3 (da) Borehulsredskab
DK3034244T3 (da) Multifunktionsværktøj
BR112015021297A2 (pt) um processo para a produção de adenovírus.
BR112017010466A2 (pt) processo para a produção de metildiclorofosfano
BR112019008819A2 (pt) Processo para a recuperação de furfural
BR112018002930A2 (pt) processo para preparação de um composto.
BR112016019608A2 (pt) processo para purificação de polissacarídeos de men-c
DK3170627T3 (da) Redskab
BR112016025076A2 (pt) processo para a preparação de ciclosserinas substituídas
DK3166923T3 (da) Fremgangsmåde til fremstilling af substituerede phenylalkaner
BR112017002873A2 (pt) processo para preparar intermediários sintéticos para preparar derivados de tetra-hidroquinolina
DK3206886T3 (da) Fremgangsmåde til at fremstille tredimensionelle strukturelle overflader
BR112016027819A2 (pt) Processo de preparação de derivados de tiazole
BR112016019246A2 (pt) processo paraa fabricação de hidroclorofluoro-olefinas
MA46454A (fr) Procédé multi-protéase
ES2789757T8 (es) Herramienta de conformado
BR112016029516A2 (pt) métodos para a produção de produtos químicos com interrupções de operação
BR112016019843A2 (pt) processo de biorrefinamento
ITBA20140018A1 (it) Macchinario per la produzione di stracciatella
BR112017000697A2 (pt) “processo para a produção de compostos de biaril”
FI20145416A (fi) Tulostusjärjestelmä

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 401/12

Ipc: C07D 401/12 (2006.01), C07D 239/56 (2006.01), C07D

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/02/2015, OBSERVADAS AS CONDICOES LEGAIS